MARTIN E. KATZ, M.D.; PETER E. SCHWARTZ, M.D.; DANIEL S. KAPP, M.D.; SHARON LUIKART, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Dr. Bruckner's letter in the November 1981 issue written in response to our recent review of epithelial carcinoma of the ovary raises several important questions about the results of therapy in women with ovarian cancer. It is clear that all clinical studies reported need to be analyzed for important variables that may modify response rates, disease-free survival, and overall survival. These important variables include stage of disease, degree of tumor differentiation, previous exposure to radiation therapy and chemotherapy, performance status, and completeness of restaging. It is also important that clinical trials be done in a prospective, randomized
KATZ ME, SCHWARTZ PE, KAPP DS, et al. Ovarian Cancer. Ann Intern Med. 1982;96:532–533. doi: https://doi.org/10.7326/0003-4819-96-4-532
Download citation file:
Published: Ann Intern Med. 1982;96(4):532-533.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use